Cannabidiol is under clinical development by Bod Science and currently in Phase I for Pain. According to GlobalData, Phase I drugs for Pain have a 75% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Cannabidiol’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Cannabidiol overview

Xativa is under development for the treatment of inflammation condition, anxiety and movement disorders like tremor, insomnia and pain. It is formulated as a wafer and administered through sublingual route. The drug candidate is being developed based on the WaferiX sublingual technology. The drug candidate is a cannabidiol product which acts by targeting cannabinoid receptor 1 and cannabinoid receptor 2.

It was also under development for the treatment of epilepsy, multiple sclerosis, pain, post chemotherapy nausea and vomiting.

Bod Science overview

Bod Science, formerly BOD Australia Limited, is a developer, manufacturer, distributor, importer, exporter and marketer of products for the skincare, beauty, and health industries. Its brand portfolio includes: BIO EFFECT, a protein that speeds up the skins natural renewal process to rejuvenate the complexion and banish signs of ageing; PINPOINT, enhances memory, concentration and calmness; Flexofytol, an anti-inflammatory and Pommade Devine brands which serves as a natural skincare remedy that helps in quick repair and deeply nourish dry damaged skin. The company distributes its products through multi-channel network of partner retailers including the spa industry, department stores and specialty retailers, online, TVSN (Home shopping Network), pharmacies and naturopathy and natural health providers. Bod Science is headquartered in New South Wales, Australia.

For a complete picture of Cannabidiol’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 2 September 2023

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.